Walter Byrd, MD
Psychiatry · Morgantown, WVNPI 1427023985
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $218,103 of the $299,345 with a category attached, or 72.9%. 11 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 48.5% of the total. Reporting peaked in 2019 at $172,094 and has fallen 68.7% since, to $53,871 in 2025. Among psychiatry clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 390 payments — averaging $767.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$145K
- Neurocrine Biosciences, Inc.$87K
- E.r. Squibb & Sons, L.L.C.$28K
- Sunovion Pharmaceuticals Inc.$18K
- Johnson & Johnson$12K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- plus $2K from 5 others
What the payments were for
- Consulting fees$38,94013%
- Speaking & faculty fees$218,10373%
- Travel & lodging$33,86811%
- Food & beverage$8,3313%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 193 | $145,208 |
| Neurocrine Biosciences, Inc. | 105 | $86,913 |
| E.r. Squibb & Sons, L.L.C. | 24 | $27,791 |
| Sunovion Pharmaceuticals Inc. | 20 | $18,055 |
| Johnson & Johnson | 21 | $12,412 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $7,406 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $655 |
| AbbVie | 4 | $329 |
| Alkermes, Inc. | 3 | $298 |
| Axsome Therapeutics, Inc. | 3 | $246 |
| Tris Pharma Inc | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$105,025
- INGREZZA$84,299
- ABILIFY MAINTENA$39,792
- LATUDA$17,816
- SPRAVATO$12,068
- TRINTELLIX$7,242
- LYBALVI$420
- VRAYLAR$125
- Auvelity$100
How this compares
$299,345 in reported general payments places this provider in the 95th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 29 | $81,860 |
| RexultiBrexpiprazole | 25 | $37,373 |
| BrixadiBuprenorphine | 12 | $20,423 |
| Risperdal ConstaRisperidone Microspheres | 12 | $14,833 |
| TrintellixVortioxetine Hydrobromide | 22 | $11,064 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 45 | $7,432 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $6,174 |
| EliquisApixaban | 11 | $6,149 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 35 | $1,810 |
| Acamprosate Calcium | 13 | $1,512 |
| Clozapine | 23 | $1,496 |
| Bupropion XlBupropion Hcl | 51 | $1,154 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 38 | $1,080 |
| Pregabalin | 14 | $956 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 31 | $943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $12,412 | $96,69441 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $145,208 | $37,37325 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $7,406 | $17,23838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 psychiatry providers in West Virginia.
Other psychiatry in Morgantown
- Francis YslaMorgantown$7K
- Melissa AlbertMorgantown$4K
- Wanhong ZhengMorgantown$3K
- John VaninMorgantown$1K
- Melissa MoodyCharleston$1.2M
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
- Daniel ThistlethwaiteSouth Charleston$468K
- Fahd MousaCharleston$200K
- Debra StultzBarboursville$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.